Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.
Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.
Our news collection prioritizes accuracy and timeliness, offering:
• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news
Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.
Enveric Biosciences (NASDAQ: ENVB) is hosting a virtual fireside chat with Chief Medical Officer Dr. Bob Dagher on May 17, 2022, at 10:00 a.m. EDT. Dr. Dagher, with over 20 years of experience in neuroscience, will discuss the psychedelic industry and Cancer Related Distress, showcasing Enveric's unique approach to psychedelic therapeutics. He will also outline anticipated milestones for 2022. Interested participants can register for the event here.
Enveric Biosciences Inc (NASDAQ: ENVB) announced a dividend of one one-thousandth of a share of newly-designated Series C Preferred Stock for each outstanding share of common stock, effective for holders as of May 13, 2022. The Series C Preferred Stock will provide substantial voting rights and will be redeemable under specific circumstances. The company emphasizes its focus on developing psychedelic-inspired mental health medicines for conditions such as cancer-related distress and PTSD. Further details will be posted in a Form 8-K with the SEC.
Enveric Biosciences (NASDAQ: ENVB) announced its participation in three investor conferences in April 2022. Dr. Joseph Tucker, CEO, will speak at the Benzinga Psychedelics Capital Conference on April 19 at 11:10 a.m. ET in Miami, FL; the Sequire Cannabis & Psychedelic Conference on April 20 at 1:00 p.m. ET virtually; and the KCSA Psychedelics Investor Conference on April 27 at 11:00 a.m. ET, also virtually. Interested attendees can register for these events through the provided links.
Enveric Biosciences (NASDAQ: ENVB) reported a comprehensive net loss of $48.8 million for the year ending December 31, 2021, up from $7.0 million in 2020. The loss per share was $2.07. The company ended 2021 with $17.4 million in cash and equivalents. Key milestones included the acquisition of MagicMed and positive preclinical data for EV102. Enveric also filed several patent applications to strengthen its intellectual property portfolio and closed a $10 million public offering to support its drug development efforts.
Enveric Biosciences (NASDAQ: ENVB) has filed a provisional patent application for over 100 novel molecules, potentially leading to 10,000 new drug candidates. This initiative is part of their second-generation program targeting cancer-related distress (CRD) and expanding into other mental health conditions. Chief Innovation Officer Dr. Peter Facchini noted the use of their PsyAI™ technology in molecule design. These molecules, synthesized for safety evaluation, may advance to preclinical development soon. The application aims to address significant psychological distress in cancer patients, where existing treatments have shown limited efficacy.
Enveric Biosciences (NASDAQ: ENVB) announced the publication of its first four Patent Cooperation Treaty (PCT) applications for novel tryptamine molecules aimed at treating psychiatric and neurological disorders. These applications, published by the World Intellectual Property Organization (WIPO), protect Enveric’s innovative drug candidates, positioning the company as a leader in the development of psychedelic-inspired therapies. Tryptamines, including well-known psychedelics, are under research for their potential therapeutic advantages in various mental health conditions.
Enveric Biosciences (NASDAQ: ENVB) announced CEO Dr. Joseph Tucker's participation in three investor conferences in March 2022. The events include the Q1 Virtual Investor Summit on March 8 at 11:45 a.m. ET, Citi's Psychedelic Drug Call Series on March 10 at 10:00 a.m. ET, and the Maxim 2022 Virtual Growth Conference from March 28-30. Attendees can register online for each conference. Enveric focuses on developing psychedelic-inspired mental health medicines to aid patients suffering from conditions like cancer-related distress and PTSD.
Enveric Biosciences (NASDAQ: ENVB) has filed its 10th Patent Cooperation Treaty (PCT) application focused on tryptamine-based derivative molecules, enhancing its intellectual property portfolio related to psychedelic-inspired mental health treatments. These novel compounds are linked to substances like DMT and psilocybin, which are being researched for various psychiatric disorders. Enveric aims to improve the commercial and regulatory prospects of these compounds and plans to explore out-licensing collaborations with other drug developers to maximize therapeutic potential.
Enveric Biosciences (NASDAQ: ENVB) is collaborating with the University of Calgary's Hotchkiss Brain Institute to launch a clinical trial for EVM-101, aimed at treating Cancer Related Distress (CRD). Approximately 50% of cancer patients experience significant psychological distress, highlighting a pressing medical need for effective treatments. The trial will assess the efficacy of a psilocybin-based therapy on CRD symptoms, with patient enrollment expected to begin in late 2022 or early 2023. Enveric is focused on developing innovative psychedelic-inspired mental health medications.
Enveric Biosciences (NASDAQ: ENVB) has closed its underwritten public offering, raising approximately $10 million through the sale of 20,000,000 shares of common stock and warrants. After costs, the company received net proceeds of about $9.2 million. The funds will be allocated for working capital and general corporate purposes. The offering included a 45-day option for the underwriter to purchase an additional 3,000,000 shares and/or warrants. This public offering was conducted under an effective shelf registration statement with the SEC.